Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ARAY 
Accuray Incorporated (ARAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.52
1 Year Target Price $2.52
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.45M USD | Price to earnings Ratio - | 1Y Target Price 2.52 |
Price to earnings Ratio - | 1Y Target Price 2.52 | ||
Volume (30-day avg) 4 | Beta 1.15 | 52 Weeks Range 0.50 - 2.10 | Updated Date 02/24/2026 |
52 Weeks Range 0.50 - 2.10 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-04 | When - | Estimate -0.11 | Actual -0.1076 |
Profitability
Profit Margin -8.15% | Operating Margin (TTM) 3.73% |
Management Effectiveness
Return on Assets (TTM) -1.18% | Return on Equity (TTM) -70.32% |
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 304948836 | Price to Sales(TTM) 0.16 |
Enterprise Value 304948836 | Price to Sales(TTM) 0.16 | ||
Enterprise Value to Revenue 0.67 | Enterprise Value to EBITDA 15.07 | Shares Outstanding 118782630 | Shares Floating 113007419 |
Shares Outstanding 118782630 | Shares Floating 113007419 | ||
Percent Insiders 4.08 | Percent Institutions 70.95 |
Upturn AI SWOT
Accuray Incorporated
Company Overview
History and Background
Accuray Incorporated was founded in 1990. It emerged from the research and development efforts of Tomo Therapy. A significant milestone was the introduction of the CyberKnife system, revolutionizing image-guided robotic radiosurgery. The company has since focused on developing and commercializing advanced radiation oncology systems.
Core Business Areas
- Radiation Oncology Systems: Accuray designs, manufactures, and sells innovative systems for delivering radiation therapy to treat cancer. This includes their flagship CyberKnife and TomoTherapy platforms, which offer precision targeting and advanced treatment capabilities.
- Software and Services: The company also provides associated software for treatment planning and delivery, as well as comprehensive service and support for their installed base of systems.
Leadership and Structure
Accuray Incorporated is led by a management team with expertise in the medical device and healthcare industries. The organizational structure is typically segmented by product lines, sales, marketing, research and development, and global operations.
Top Products and Market Share
Key Offerings
- CyberKnife: A robotic, image-guided radiosurgery system designed for precise, non-invasive tumor treatment anywhere in the body. Competitors include Varian Medical Systems (Rad/IR Suite), Elekta (Leksell Gamma Knife), and Brainlab (ExacTrac).
- TomoTherapy: An integrated radiation therapy system combining a linear accelerator with a CT scanner for advanced helical IMRT and image guidance. Competitors include Varian Medical Systems (TrueBeam, Edge), Elekta (Versa HD, Infinity), and MedAust Austria (Proton Therapy).
Market Dynamics
Industry Overview
The radiation oncology market is characterized by continuous technological advancements aimed at improving treatment precision, patient outcomes, and workflow efficiency. Key trends include the adoption of image-guided radiation therapy (IGRT), adaptive radiotherapy, and proton therapy. The market is driven by an aging global population, increasing cancer incidence, and healthcare spending.
Positioning
Accuray is positioned as a leading innovator in precision radiation oncology, particularly recognized for its advanced image guidance and robotic delivery systems like CyberKnife. Its competitive advantage lies in its differentiated technologies that offer highly accurate, non-invasive treatment options for a wide range of cancers.
Total Addressable Market (TAM)
The global radiation oncology market is substantial and projected to grow significantly. While specific TAM figures vary by report, it is estimated to be in the tens of billions of dollars. Accuray addresses a significant portion of this market with its advanced radiotherapy systems.
Upturn SWOT Analysis
Strengths
- Innovative technology with a strong focus on precision and image guidance.
- Established reputation for the CyberKnife and TomoTherapy platforms.
- Global installed base providing recurring service revenue.
- Strong intellectual property portfolio.
Weaknesses
- High capital expenditure required for their systems can be a barrier for some healthcare providers.
- Intense competition from larger, more diversified medical device companies.
- Dependence on a relatively small number of key products.
- Historically, profitability has been inconsistent.
Opportunities
- Expansion into emerging markets with growing healthcare infrastructure.
- Development of new applications and treatment modalities for their existing platforms.
- Strategic partnerships and collaborations to broaden market reach.
- Growing demand for minimally invasive cancer treatments.
Threats
- Rapid technological advancements by competitors could render existing products less competitive.
- Changes in healthcare reimbursement policies and regulatory landscapes.
- Economic downturns impacting healthcare capital spending.
- Supply chain disruptions affecting manufacturing and delivery.
Competitors and Market Share
Key Competitors
- Varian Medical Systems (VAR)
- Elekta AB (EKTA B.ST)
- GE Healthcare (GE)
- Philips Healthcare (PHG)
Competitive Landscape
Accuray faces strong competition from larger players with broader product portfolios and extensive global reach. Its competitive advantage lies in its specialized focus on precision radiation oncology and its unique technological offerings, particularly for complex treatment scenarios. However, larger competitors often have greater financial resources for R&D and marketing.
Growth Trajectory and Initiatives
Historical Growth: Accuray has demonstrated historical growth in its installed base and associated service revenue. However, top-line growth has been subject to the cyclical nature of capital equipment sales in the healthcare industry.
Future Projections: Analyst projections for Accuray's future growth typically depend on new product introductions, market penetration strategies, and the overall health of the oncology market. Focus is often on increasing recurring service revenue and expanding into new geographic regions.
Recent Initiatives: Recent initiatives may include the launch of new product enhancements, strategic partnerships to expand market access, and efforts to optimize operational efficiency and cost management.
Summary
Accuray Incorporated is a specialized player in the radiation oncology market, known for its innovative CyberKnife and TomoTherapy systems. The company's strengths lie in its advanced technology and established product lines, offering precision cancer treatments. However, it faces significant competition from larger, more diversified medical device companies and can be impacted by the high capital costs of its equipment. Future success will depend on continued innovation, strategic market expansion, and improved financial stability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Accuray Incorporated Investor Relations
- Industry research reports on the radiation oncology market
- Financial news and data providers
Disclaimers:
This information is for informational purposes only and should not be considered investment advice. Market share data and financial metrics are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accuray Incorporated
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Mr. Stephen R. LaNeve MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 990 | Website https://www.accuray.com |
Full time employees 990 | Website https://www.accuray.com | ||
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.